Movement Alert｜DUALITYBIO-B Rises 5.12% in Regular Trading, Innovative Drug Sector Rally and Interim Results Approaching

Market Focus

Yesterday

On August 25, DUALITYBIO-B rose 5.12% in regular trading, trading at HK$199.8/share, with turnover of HK$27.67 million.

On the news front, the Hong Kong-listed innovative drug sector was broadly active, with multiple peers including Everest Medicines and Remegen posting strong gains, providing sector-level momentum. At the company level, UBS recently initiated coverage with a \"Buy\" rating and a target price of HK$320, implying approximately 62% upside from current levels. Zhongshang Securities, Dongwu Securities, and China Galaxy Securities had also previously initiated coverage with positive ratings.

Additionally, DUALITYBIO-B is scheduled to release its interim results on August 28, with market focus on cash burn rate and commercialization progress. The company has conducted continuous share buybacks since early June, with institutional bullish sentiment and earnings release expectations forming a near-term catalyst convergence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1186876654"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186876654\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186876654?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-25 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186876654","market":"hk","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Rises 5.12% in Regular Trading, Innovative Drug Sector Rally and Interim Results Approaching","media":"Market Focus","content":"<p><p>On August 25, DUALITYBIO-B rose 5.12% in regular trading, trading at HK$199.8/share, with turnover of HK$27.67 million.</p><p>On the news front, the Hong Kong-listed innovative drug sector was broadly active, with multiple peers including Everest Medicines and Remegen posting strong gains, providing sector-level momentum. At the company level, UBS recently initiated coverage with a \\\"Buy\\\" rating and a target price of HK$320, implying approximately 62% upside from current levels. Zhongshang Securities, Dongwu Securities, and China Galaxy Securities had also previously initiated coverage with positive ratings.</p><p>Additionally, DUALITYBIO-B is scheduled to release its interim results on August 28, with market focus on cash burn rate and commercialization progress. The company has conducted continuous share buybacks since early June, with institutional bullish sentiment and earnings release expectations forming a near-term catalyst convergence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Rises 5.12% in Regular Trading, Innovative Drug Sector Rally and Interim Results Approaching</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Rises 5.12% in Regular Trading, Innovative Drug Sector Rally and Interim Results Approaching\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-25 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 25, DUALITYBIO-B rose 5.12% in regular trading, trading at HK$199.8/share, with turnover of HK$27.67 million.</p><p>On the news front, the Hong Kong-listed innovative drug sector was broadly active, with multiple peers including Everest Medicines and Remegen posting strong gains, providing sector-level momentum. At the company level, UBS recently initiated coverage with a \\\"Buy\\\" rating and a target price of HK$320, implying approximately 62% upside from current levels. Zhongshang Securities, Dongwu Securities, and China Galaxy Securities had also previously initiated coverage with positive ratings.</p><p>Additionally, DUALITYBIO-B is scheduled to release its interim results on August 28, with market focus on cash burn rate and commercialization progress. The company has conducted continuous share buybacks since early June, with institutional bullish sentiment and earnings release expectations forming a near-term catalyst convergence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1186876654","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186876654","pubTimestamp":1787623940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 25, DUALITYBIO-B rose 5.12% in regular trading, trading at HK$199.8/share, with turnover of HK$27.67 million.On the news front, the Hong Kong-listed innovative drug sector was broadly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势提醒|DUALITYBIO-B常规交易上涨5.12%，创新药板块反弹，中期业绩临近","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On August 25, DUALITYBIO-B rose 5.12% in regular trading, trading at HK$199.8/share, with turnover of HK$27.67 million.On the news front, the Hong Kong-listed innovative drug sector was broadly active, with multiple peers including Everest Medicines and Remegen posting strong gains, providing sector-level momentum. At the company level, UBS recently initiated coverage with a \\\"Buy\\\" rating and a target price of HK$320, implying approximately 62% upside from current levels. Zhongshang Securities, Dongwu Securities, and China Galaxy Securities had also previously initiated coverage with positive ratings.Additionally, DUALITYBIO-B is scheduled to release its interim results on August 28, with market focus on cash burn rate and commercialization progress. The company has conducted continuous share buybacks since early June, with institutional bullish sentiment and earnings release expectations forming a near-term catalyst convergence.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}